Shenzhen Shenyi Technology Secures Over 10 Million Yuan in Angel Round Funding to Democratize AI-Driven BCI

The current funding round will primarily be used for core brain-computer interface (BCI) technology R&D, mass production of consumer-grade products, and overseas market expansion, as well as clinical validation and registration conversion for medical-grade products such as auxiliary depression diagnosis and neuromodulation.

Founded in May 2025, Shenyi Technology focuses on cross-disciplinary innovation in AI + brain science. Centering on sleep disorders, depression, and various brain diseases, it develops brain function monitoring and intervention products based on artificial intelligence, non-invasive BCI, and neuromodulation technologies.

▲ The cross-disciplinary integration of AI and brain science is opening up new imaginative spaces for brain health management.

 

01  "Serious Medical + Consumer Health": A Dual-Track Collaborative Development Path

From its inception, Shenyi Technology established a dual-track collaborative development path combining "serious medical" and "consumer health."

On one hand, focusing on clinical needs such as sleep disorders and depression, the company continues to lay out EEG-based auxiliary diagnosis and precise neuromodulation technologies—including electrical stimulation, temporal interference (TI) stimulation, and acoustic-electrical combined stimulation—to build a technological moat.

On the other hand, through wearable BCI products, it lowers the barrier for brain function monitoring and intervention to enter daily life. Relying on the rapid large-scale application of consumer products, the company continuously accumulates large-scale, real-world EEG and multimodal data. This feeds back into algorithm training, individualized model optimization, and product iteration, forming a data flywheel of "user growth—data accumulation—algorithm enhancement—experience optimization.

 

02  From Brain Function Monitoring to "Monitoring + Intervention"

Medical End: Building a Closed-Loop Diagnosis and Treatment System for Non-Invasive Precise Neuromodulation

▲ Precisely focusing on neuromodulation

On the medical front, Shenyi Technology focuses on non-invasive precise deep brain neuromodulation. Centering on neuropsychiatric disorders such as sleep disorders and depression, it builds a diagnosis and treatment closed-loop spanning objective EEG assessment, individualized solution decision-making, and precise stimulation intervention.

The company's inaugural medical product is a closed-loop temporal interference (TI) electrical stimulation device. It not only achieves non-invasive precise stimulation of deep brain regions but also dynamically optimizes stimulation protocols through real-time multimodal monitoring feedback. According to the team, this product is also the first domestically developed closed-loop TI neuromodulation device aimed at industrialization, distinguishing it from current technology routes that mostly rely on one-way stimulation.

Building on this, Shenyi Technology is also strategically developing multimodal acoustic-electrical combined stimulation technology, exploring neuromodulation solutions with higher precision and greater individualization capabilities through the synergy of focused ultrasound and electrical stimulation. According to the team, Shenyi Technology is the first in China to systematically lay out the industrialization of multimodal acoustic-electrical combined stimulation, gradually building a precise neuromodulation technology platform covering different targets, depths, and disease stages.

Consumer End: Enabling BCI to Seamlessly Enter Daily Life

▲ Wearable BCI products integrate sleep and emotion management into daily life

On the consumer front, Shenyi Technology uses wearable BCI products as an entry point. Combined with AI algorithms, it continuously analyzes users' brain states related to sleep and emotions, and further explores adaptive interventions based on individual brain states.

Centering on the popularization of BCI applications, the company is continuously advancing hardware miniaturization, algorithmic intelligence, and imperceptible usage. By minimizing the volume of EEG acquisition modules to the extreme, it reduces power consumption and wearing burden. Simultaneously, it utilizes AI to enhance EEG signal processing, brain state recognition, and individualized analysis capabilities in complex environments, allowing BCI to gradually enter sleep, emotion, and daily brain health management scenarios.

Addressing the brain health management needs of healthy individuals, as well as the diagnosis and treatment needs of patients with varying degrees of brain diseases, Shenyi Technology will gradually establish a tiered product system covering daily brain health management, home interventions for mild populations, in-hospital treatment for moderate to severe patients, and long-term out-of-hospital management. This promotes the extension of brain function monitoring and precise intervention capabilities from hospitals to homes and daily life scenarios.

 

03  Backed by Market Capital and National-Level Industry Platforms

The lead investor for this round is the Shenzhen Guangming Leaguer Science City Seed Venture Capital Fund Partnership (L.P.) (hereinafter referred to as the "Guangming Leaguer Fund"), under Leaguer Venture Capital.

Leaguer Venture Capital has long focused on early-stage technological innovation, adhering to the principle of "investing early, investing small, investing in hard tech," and strategically laying out tech enterprises with core technological barriers and industrialization potential. The Guangming Leaguer Fund was established with contributions from the Shenzhen Angel Mother Fund, Guangming District Guidance Fund, and Leaguer Kechuang.

BCI is currently accelerating its evolution from frontier technology validation to large-scale industrial implementation. Shenyi Technology has built a relatively complete technological system around EEG acquisition, AI algorithms, precise neuromodulation, and engineering. Through its dual-track layout of "serious medical + consumer health," it has formed a development path that balances short-term commercial validation with the construction of long-term technological, clinical, and regulatory barriers, possessing technological depth, product implementation capabilities, and industrialization potential.

— Leaguer Venture Capital

 

The co-investor for this round, Dongguan Biotech, focuses on frontier fields such as biomedicine, medical devices, and life and health.

Neuropsychiatric diseases like depression have significant long-term, tiered diagnosis and treatment needs. Centering on objective EEG assessment and precise neuromodulation, Shenyi Technology is gradually building a tiered product system covering patients with mild to moderate-to-severe depression, and promoting the extension of brain function monitoring and intervention capabilities from hospitals to homes. This holds clear clinical value and space for large-scale application.

— Dongguan Biotech

 

In addition to this round's investors, one of the founding shareholders of Shenyi Technology is Shenzhen National Research Institute of High-Performance Medical Devices Co., Ltd., which is the operating entity of the National Innovation Center for High-Performance Medical Devices.

The center is Shenzhen's first national-level manufacturing innovation center, jointly initiated and established by research institutions, universities, and leading medical device enterprises such as the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Mindray Medical, United Imaging Healthcare, Lifetech, and Harbin Institute of Technology. It has long promoted the R&D and industrial transformation of key common technologies for high-performance medical devices.

BCI is a frontier field deeply intersecting artificial intelligence, neuroscience, and high-end medical devices...